ECG-triggered 18F-fluorodeoxyglucose positron emission tomography imaging of the rat heart is dramatically enhanced by acipimox

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 37, Issue 9, 2010, Pages 1745-1750

  Poussier, Sylvain ^a,b,c,e   Maskali, Fatiha ^a,b   Tran, Nguyen ^c,d   Person, Christophe ^a,b,c   Maureira, Pablo ^b,c   Boutley, Henri ^a,b,c   Karcher, Gilles ^a,b,c   Lacolley, Patrick ^c,d   Régnault, Véronique ^c,d   Fay, Renaud ^d   Marie, Pierre Yves ^a,b,c,d  

^a Nancyclotep   (France)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

^c UNIVERSITÉ DE LORRAINE   (France)

^d INSERM   (France)

^e CHU NANCY BRABOIS   (France)

Author keywords

Acipimox; FDG; LV function; PET; Rats

Indexed keywords

ACIPIMOX; FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; GLUCOSE; PYRAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; DRUG DOSE COMPARISON; ELECTROCARDIOGRAM; HEART; HEART LEFT VENTRICLE FUNCTION; IMAGE QUALITY; MALE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; POSITRON EMISSION TOMOGRAPHY; RAT; SIGNAL NOISE RATIO; ANIMAL; CARDIAC GATED IMAGING; DOSE RESPONSE; DRUG EFFECT; ELECTROCARDIOGRAPHY; METHODOLOGY; PHYSIOLOGY; SCINTISCANNING; WISTAR RAT;

ANIMALS; CARDIAC-GATED IMAGING TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; FLUORODEOXYGLUCOSE F18; GLUCOSE; HEART; MALE; POSITRON-EMISSION TOMOGRAPHY; PYRAZINES; RATS; RATS, WISTAR; VENTRICULAR FUNCTION, LEFT;

EID: 77956189819     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-010-1418-0     Document Type: Article

References (26)

1. PG Camici 2003 Gated PET and ventricular volume J Nucl Med 44 10 1662 14530483
2. RH Slart JJ Bax RM de Jong J de Boer HJ Lamb PH Mook AT Willemsen, et al. 2004 Comparison of gated PET with MRI for evaluation of left ventricular function in patients with coronary artery disease J Nucl Med 45 2 176 182 14960633
3. WM Schaefer CS Lipke B Nowak HJ Kaiser A Buecker GA Krombach, et al. 2003 Validation of an evaluation routine for left ventricular volumes, ejection fraction and wall motion from gated cardiac FDG PET: a comparison with cardiac magnetic resonance imaging Eur J Nucl Med Mol Imaging 30 4 545 553 12589480
4. B Hesse K Tägil A Cuocolo C Anagnostopoulos M Bardiés J Bax EANM/ESC Group, et al. 2005 EANM/ESC procedural guidelines for myocardial perfusion imaging in nuclear cardiology Eur J Nucl Med Mol Imaging 32 7 855 897 10.1007/s00259-005-1779-y 1:STN:280:DC%2BD2Mzpt1Kjsg%3D%3D 15909197
5. JJ Bax MA Veening FC Visser A van Lingen RJ Heine JH Cornel, et al. 1997 Optimal metabolic conditions during fluorine-18 fluorodeoxyglucose imaging; a comparative study using different protocols Eur J Nucl Med 24 1 35 41 10.1007/BF01728306 1:STN:280:DyaK2s7htlWntA%3D%3D 9044874
6. MJ Knuuti H Yki-Järvinen LM Voipio-Pulkki M Mäki U Ruotsalainen R Härkönen, et al. 1994 Enhancement of myocardial [fluorine-18]fluorodeoxyglucose uptake by a nicotinic acid derivative J Nucl Med 35 6 989 998 1:CAS:528:DyaK2cXlslCju74%3D 8195886
7. JJ Bax FC Visser D Poldermans A Van Lingen A Elhendy E Boersma, et al. 2002 Safety and feasibility of cardiac FDG SPECT following oral administration of Acipimox, a nicotinic acid derivative: comparison of image quality with hyperinsulinemic euglycemic clamping in nondiabetic patients J Nucl Cardiol 9 6 587 593 10.1067/mnc.2002.125391 12466782
8. O Schröder G Hör A Hertel RP Baum 1998 Combined hyperinsulinaemic glucose clamp and oral acipimox for optimizing metabolic conditions during 18F-fluorodeoxyglucose gated PET cardiac imaging: comparative results Nucl Med Commun 19 9 867 874 10.1097/00006231-199809000-00007 10581593
9. T Kudo K Fukuchi AJ Annala AF Chatziioannou V Allada M Dahlbom, et al. 2002 Noninvasive measurement of myocardial activity concentrations and perfusion defect sizes in rats with a new small-animal positron emission tomograph Circulation 106 1 118 123 10.1161/01.CIR.0000020221.28996.78 12093780
10. D Thomas H Bal J Arkles J Horowitz L Araujo PD Acton, et al. 2008 Noninvasive assessment of myocardial viability in a small animal model: comparison of MRI, SPECT, and PET Magn Reson Med 59 2 252 259 10.1002/mrm.21445 18228591
11. C Chapon JS Jackson EO Aboagye AH Herlihy WA Jones KK Bhakoo 2009 An in vivo multimodal imaging study using MRI and PET of stem cell transplantation after myocardial infarction in rats Mol Imaging Biol 11 1 31 38 10.1007/s11307-008-0174-z 18773246
12. E Croteau F Bénard J Cadorette ME Gauthier A Aliaga M Bentourkia, et al. 2003 Quantitative gated PET for the assessment of left ventricular function in small animals J Nucl Med 44 10 1655 1661 14530482
13. K Nakagawa H Namba M Iyo K Fukushi T Irie M Yamanouchi, et al. 1995 Simplified PET quantitation of myocardial glucose utilization J Nucl Med 36 11 2094 2102 1:CAS:528:DyaK28XjvFChsg%3D%3D 7472605
14. H Namba K Nakagawa M Iyo K Fukushi T Irie 1994 A simple method for measuring glucose utilization of insulin-sensitive tissues by using the brain as a reference Eur J Nucl Med 21 3 228 231 10.1007/BF00188671 1:CAS:528: DyaK2cXlslCnsbo%3D 8200391
15. T Higuchi SG Nekolla A Jankaukas AW Weber MC Huisman S Reder, et al. 2007 Characterization of normal and infarcted rat myocardium using a combination of small-animal PET and clinical MRI J Nucl Med 48 2 288 294 17268027
16. E Carballo-Jane LS Gerckens S Luell AS Parlapiano M Wolff SL Colletti, et al. 2007 Comparison of rat and dog models of vasodilatation and lipolysis for the calculation of a therapeutic index for GPR109A agonists J Pharmacol Toxicol Methods 56 3 308 316 10.1016/j.vascn.2007.05.007 1:CAS:528:DC%2BD2sXhtFGkt7zL 17643322
17. JC Blachère F Pérusse LJ Bukowiecki 2001 Lowering plasma free fatty acids with Acipimox mimics the antidiabetic effects of the beta 3-adrenergic agonist CL-316243 in obese Zucker diabetic fatty rats Metabolism 50 8 945 951 10.1053/meta.2001.24868 11474483
18. BJ Kemp CB Hruska AR McFarland MW Lenox VJ Lowe 2009 NEMA NU 2-2007 performance measurements of the Siemens Inveon preclinical small animal PET system Phys Med Biol 54 8 2359 2376 10.1088/0031-9155/54/8/007 19321924
19. EP Visser JA Disselhorst M Brom P Laverman M Gotthardt WJ Oyen, et al. 2009 Spatial resolution and sensitivity of the Inveon small-animal PET scanner J Nucl Med 50 1 139 147 10.2967/jnumed.108.055152 19139188
20. F Maskali PR Franken S Poussier N Tran C Vanhove H Boutley, et al. 2006 Initial infarct size predicts subsequent cardiac remodeling in the rat infarct model: an in vivo serial pinhole gated SPECT study J Nucl Med 47 2 337 344 16455641
21. J Nishikawa T Ohtake I Yokoyama T Watanabe T Momose Y Sasaki 1996 Simple method to quantify myocardial glucose metabolism from MB ratio in myocardial FDG PET Ann Nucl Med 10 3 323 328 10.1007/BF03164739 1:CAS:528:DyaK28XmslKksLg%3D 8883708
22. J Vom Dahl WH Herman RJ Hicks FJ Ortiz-Alonso KS Lee KC Allman, et al. 1993 Myocardial glucose uptake in patients with insulin-dependent diabetes mellitus assessed quantitatively by dynamic positron emission tomography Circulation 88 395 404 1:STN:280:DyaK3szjvVylsg%3D%3D 8339403
23. PY Marie W Djaballah PR Franken C Vanhove MA Muller H Boutley, et al. 2005 OSEM reconstruction, associated with temporal Fourier and depth-dependant resolution recovery filtering, enhances results from sestamibi and 201Tl 16-interval gated SPECT J Nucl Med 46 1789 1795 16269591
24. AF Schinkel JJ Bax R Valkema A Elhendy RT van Domburg EC Vourvouri, et al. 2003 Effect of diabetes mellitus on myocardial 18F-FDG SPECT using acipimox for the assessment of myocardial viability J Nucl Med 44 877 883 12791813
25. H Tuunanen E Engblom A Naum K Någren B Hesse KE Airaksinen, et al. 2006 Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure Circulation 114 20 877 883 10.1161/CIRCULATIONAHA. 106.645184
26. P Nuutila MJ Knuuti M Raitakari U Ruotsalainen M Teräs LM Voipio-Pulkki, et al. 1994 Effect of antilipolysis on heart and skeletal muscle glucose uptake in overnight fasted humans Am J Physiol 267 6 Pt 1 E941 E946 1:CAS:528:DyaK2MXivFKntrw%3D 7810638